Serum Cardiac Troponin T Levels as a Therapy Response Marker in Tofersen‐Treated ALS
Open Access
- 9 June 2025
- journal article
- Published by Wiley in Muscle & Nerve
- Vol. 72 (3) , 509-514
Abstract
Introduction/Aims: Cardiac troponin T (cTnT) levels are elevated in the majority of persons with amyotrophic lateral sclerosis (ALS) and increase over time. Neurofilament light chain (NfL) is an established therapy response biomarker in ALS as superoxide dismutase1 (SOD1)‐ALS patients treated with the antisense oligonucleotide tofersen show a decrease in NfL. In this study, we assess cTnT levels in SOD1‐ALS at baseline and during tofersen treatment.Methods: cTnT was analyzed at baseline and during tofersen treatment in 23 SOD1‐ALS patients at two specialized ALS centers in Germany and compared to a control cohort of 74 ALS patients without SOD1 variants.Results: cTnT levels increased in the control ALS cohort over time (p < 0.0001) but not in the tofersen group (p = 0.36). Creatine kinase (CK) and CK‐MB levels did not show significant changes over time. The median monthly increase of cTnT was 0.045 points (IQR 0.02–0.08) in the control ALS cohort and 0.01 points (IQR −0.01–0.03) in the tofersen group (p = 0.0013). A significantly lower fold change in cTnT levels was observed in the tofersen‐treated cohort (median 1.2; IQR 0.77–1.59) relative to the control group (median 1.89; IQR 1.35–2.75) (p = 0.0003). Nine (39%) patients treated with tofersen experienced a reduction in cTnT levels.Discussion: In this study, we describe a response signal of cTnT to tofersen treatment, which supports the value of cTnT as an independent biomarker in ALS. These results contribute to the notion that cTnT may provide additional value as a progression and treatment response biomarker in ALS complementary to NfL and warrant further investigation.Keywords
This publication has 10 references indexed in Scilit:
- Cardiac troponin T as a serum biomarker of respiratory impairment in amyotrophic lateral sclerosisAnnals of Clinical and Translational Neurology, 2024
- Clinical and patient‐reported outcomes and neurofilament response during tofersen treatment in SOD1‐related ALS—A multicenter observational study over 18 monthsMuscle & Nerve, 2024
- Creatine Kinase MB Isoenzyme Is a Complementary Biomarker in Amyotrophic Lateral SclerosisInternational Journal of Molecular Sciences, 2023
- Neurofilament light‐chain response during therapy with antisense oligonucleotide tofersen in SOD1‐related ALS: Treatment experience in clinical practiceMuscle & Nerve, 2023
- Trial of Antisense Oligonucleotide Tofersen for SOD1 ALSNew England Journal of Medicine, 2022
- Teaching an old dog new tricks: serum troponin T as a biomarker in amyotrophic lateral sclerosisBrain Communications, 2021
- Cardiac troponin T is elevated and increases longitudinally in ALS patientsAmyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2021
- Elevation of Cardiac Troponin T, But Not Cardiac Troponin I, in Patients With Neuromuscular DiseasesJACC, 2014
- Clinical significance in the change of decline in ALSFRS-RAmyotrophic Lateral Sclerosis, 2010
- Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALSNeurology, 2006